Early-onset motor impairment and increased accumulation of phosphorylated α-synuclein in the motor cortex of normal aging mice are ameliorated by coenzyme Q.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Experimental Gerontology

• Publication date

  2016-08-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.exger.2016.04.023PMID 27143639
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Age-Dependent Effects of A53T Alpha-Synuclein on Behavior and Dopaminergic Function

  2013cited by this paper
• The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson’s disease: a review of in vivo models

  2013influential reference
• Exogenous administration of coenzyme Q10 restores mitochondrial oxygen consumption in the aged mouse brain.

  2013influential reference
• Corticostriatal connectivity and its role in disease

  2013cited by this paper
• Hierarchical Connectivity and Connection-Specific Dynamics in the Corticospinal–Corticostriatal Microcircuit in Mouse Motor Cortex

  2012cited by this paper
• Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease

  2012influential reference
• Reversal of slow growth and heartbeat through the restoration of mitochondrial function in clk-1-deficient mouse embryos by exogenous administration of coenzyme Q10.

  2012influential reference
• Mitochondria: The Next (Neurode)Generation

  2011cited by this paper
• Gabapentin blocks methamphetamine-induced sensitization and conditioned place preference via inhibition of α₂/δ-1 subunits of the voltage-gated calcium channels.

  2011cited by this paper
• Authentically Phosphorylated α-Synuclein at Ser129 Accelerates Neurodegeneration in a Rat Model of Familial Parkinson's Disease

  2011influential reference
• Mice expressing the A53T mutant form of human alpha‐synuclein exhibit hyperactivity and reduced anxiety‐like behavior

  2010cited by this paper
• Mitochondrial α-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo.

  2010cited by this paper
• Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.

  2009cited by this paper
• Complex I deficiency in Parkinson's disease frontal cortex.

  2008cited by this paper
• Neurodegeneration and Motor Dysfunction in a Conditional Model of Parkinson's Disease

  2008cited by this paper
• Mitochondrial Import and Accumulation of α-Synuclein Impair Complex I in Human Dopaminergic Neuronal Cultures and Parkinson Disease Brain*

  2008cited by this paper
• Localization of &agr;-synuclein to mitochondria within midbrain of mice

  2007cited by this paper
• Pharmacological validation of a novel home cage activity counter in mice.

  2007influential reference
• Vitamin A deficiency induces a decrease in EEG delta power during sleep in mice.

  2007influential reference
• Neuronal !-Synucleinopathy with Severe Movement Disorder in Mice Expressing A 53 T Human !-Synuclein

  2007cited by this paper
• Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease*

  2006influential reference
• Locomotor hyperactivity and alterations in dopamine neurotransmission are associated with overexpression of A53T mutant human alpha-synuclein in mice.

  2006cited by this paper
• Imaging in Parkinson's disease: the role of monoamines in behavior.

  2006cited by this paper
• Effect of coenzyme Q10 intake on endogenous coenzyme Q content, mitochondrial electron transport chain, antioxidative defenses, and life span of mice.

  2006cited by this paper
• 3,4-Dihydroxyphenylalanine Reverses the Motor Deficits in Pitx3-Deficient Aphakia Mice: Behavioral Characterization of a Novel Genetic Model of Parkinson's Disease

  2005cited by this paper
• α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease

  2005influential reference
• Alpha-synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease.

  2005influential reference
• Phosphorylated α‐synuclein in normal mouse brain

  2004cited by this paper
• Phosphorylated alpha-synuclein in normal mouse brain.

  2004cited by this paper
• Rotenone, deguelin, their metabolites, and the rat model of Parkinson's disease.

  2004cited by this paper
• Expression of vesicular glutamate transporters, VGLUT1 and VGLUT2, in cholinergic spinal motoneurons

  2004influential reference
• The mouse brain in stereotaxic coordinates

  2003influential reference
• The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review.

  2003cited by this paper
• alpha-Synuclein is phosphorylated in synucleinopathy lesions.

  2002cited by this paper
• Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein.

  2002cited by this paper
• α-Synuclein is phosphorylated in synucleinopathy lesions

  2002cited by this paper
• Complementary distribution of vesicular glutamate transporters in the central nervous system.

  2002influential reference
• Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System

  2002influential reference
• The Mouse Brain in Stereotaxic Coordinates

  2001cited by this paper
• Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter.

  2000cited by this paper
• Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons

  2000cited by this paper
• alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies.

  1998cited by this paper
• α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies

  1998cited by this paper
• Molecular genetics of succinate:quinone oxidoreductase in eukaryotes.

  1998influential reference
• Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion.

  1997cited by this paper
• Alpha-synuclein in Lewy bodies.

  1997cited by this paper
• Proton-translocation by membrane-bound NADH:ubiquinone-oxidoreductase (complex I) through redox-gated ligand conduction.

  1997influential reference
• Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats.

  1997influential reference
• Origin and functional consequences of the complex I defect in Parkinson's disease

  1996cited by this paper
• Glial cell line-derived neurotrophic factor but not transforming growth factor beta 3 prevents delayed degeneration of nigral dopaminergic neurons following striatal 6-hydroxydopamine lesion.

  1995influential reference
• Coenzyme Q content in synaptic and non-synaptic mitochondria from different brain regions in the ageing rat.

  1995cited by this paper
• Could bradykinesia in Parkinson's disease simply be compensation?

  1994influential reference
• Two binding sites of inhibitors in NADH: ubiquinone oxidoreductase (complex I). Relationship of one site with the ubiquinone-binding site of bacterial glucose:ubiquinone oxidoreductase.

  1994influential reference
• Does tremor pace repetitive voluntary motor behavior in parkinson's disease?

  1991influential reference
• Mitochondrial Complex I Deficiency in Parkinson's Disease

  1989influential reference
• Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease.

  1989influential reference
• Biochemical pathophysiology of Parkinson's disease.

  1987influential reference
• Open field and elevated plus-maze: a behavioural comparison between spontaneously hypertensive (SHR) and Wistar-Kyoto (WKY) rats and the effects of chlordiazepoxide.

  1987influential reference
• MPTP-induced parkinsonian model in mice: biochemistry, pharmacology and behavior.

  1987cited by this paper
• Parallel organization of functionally segregated circuits linking basal ganglia and cortex.

  1986cited by this paper
• The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.

  1986cited by this paper
• A simple quantitative bradykinesia test in MPTP-treated mice.

  1985cited by this paper
• Open-field behavior in mice: A diallel analysis of selected lines

  1975influential reference
• Evidence for abnormal long-loop reflexes in rigid Parkinsonian patients.

  1975influential reference
• Biochemistry of catecholamines.

  1971influential reference
• A comparison of the effects of some benzodiazepines and other drugs on aggressive and exploratory behaviour in mice and rats.

  1970cited by this paper

• Coenzyme Q10 and the Blood–Brain Barrier: An Overview

  2025cites this paper
• Coenzyme Q10 Metabolism: A Review of Unresolved Issues

  2023influential citation
• SNAP25 is a potential target for early stage Alzheimer’s disease and Parkinson’s disease

  2023cites this paper
• Neuronal Plasticity and Age-Related Functional Decline in the Motor Cortex

  2023cites this paper
• Coenzyme Q10 supplementation improves the motor function of middle-aged mice by restoring the neuronal activity of the motor cortex

  2023cites this paper
• Assessing Cellular Uptake of Exogenous Coenzyme Q10 into Human Skin Cells by X-ray Fluorescence Imaging

  2022cites this paper
• Analysis of the Effects of Ninjin’yoeito on Physical Frailty in Mice

  2022cites this paper
• COQ2 and SNCA polymorphisms interact with environmental factors to modulate the risk of multiple system atrophy and subtype disposition

  2022cites this paper
• Secondary CoQ10 deficiency, bioenergetics unbalance in disease and aging

  2021cites this paper
• Secondary coenzyme q deficiency in neurological disorders.

  2021cites this paper
• Coenzyme Q homeostasis in aging: response to non-genetic interventions.

  2021cites this paper
• Effects of Alpha-Synuclein Targeted Antisense Oligonucleotides on Lewy Body-Like Pathology and Behavioral Disturbances Induced by Injections of Pre-Formed Fibrils in the Mouse Motor Cortex

  2021cites this paper
• CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in huntington’s disease

  2020cites this paper
• Reduced Coenzyme Q10 Decelerates Senescence and Age-Related Hearing Loss in Senescence-Accelerated Mice by Activating Mitochondrial Functions.

  2020cites this paper
• Mechanisms by which autophagy regulates memory capacity in ageing

  2020cites this paper
• Water-soluble CoQ10 as A Promising Anti-aging Agent for Neurological Dysfunction in Brain Mitochondria

  2019cites this paper
• The Paradox of Coenzyme Q10 in Aging

  2019cites this paper
• Modulation of Coenzyme Q10 content and oxidative status in human dermal fibroblasts using HMG-CoA reductase inhibitor over a broad range of concentrations. From mitohormesis to mitochondrial dysfunction and accelerated aging

  2019cites this paper
• In vitro rejuvenation of brain mitochondria by the inhibition of actin polymerization

  2018cites this paper
• Ubiquinone, ubiquinol, 4-hydroxybenzoic acid… What 'coenzyme Q10' should we care about in multiple system atrophy?

  2018cites this paper
• Neuroprotective effect of α-mangostin on mitochondrial dysfunction and α-synuclein aggregation in rotenone-induced model of Parkinson’s disease in differentiated SH-SY5Y cells

  2017cites this paper
• Optic atrophy 1 mediates coenzyme Q‐responsive regulation of respiratory complex IV activity in brain mitochondria

  2017cites this paper